Temporal and molecular dynamics of human metastatic breast carcinoma cell adhesive interactions with human bone marrow endothelium analyzed by single-cell force spectroscopy by Xie, L. et al.
This is a repository copy of Temporal and molecular dynamics of human metastatic breast 
carcinoma cell adhesive interactions with human bone marrow endothelium analyzed by 
single-cell force spectroscopy.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/137179/
Version: Published Version
Article:
Xie, L., Sun, Z., Hong, Z. et al. (5 more authors) (2018) Temporal and molecular dynamics 
of human metastatic breast carcinoma cell adhesive interactions with human bone marrow
endothelium analyzed by single-cell force spectroscopy. PLoS One, 13 (9). e0204418. 
https://doi.org/10.1371/journal.pone.0204418
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Creative Commons: Public Domain Dedication 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE
Temporal andmolecular dynamics of human
metastatic breast carcinoma cell adhesive
interactions with human bonemarrow
endothelium analyzed by single-cell force
spectroscopy
Leike Xie1,2, Zhe Sun1, Zhongkui Hong1͞, Nicola J. Brown3, Olga V. Glinskii4,5,
Kate Rittenhouse-Olson6,7, Gerald A. Meininger1,4‡, Vladislav V. GlinskyID2,5‡
1 Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri, United States of
America, 2 Department of Pathology and Anatomical Sciences, School of Medicine, University of Missouri,
Columbia, Missouri, United States of America, 3 Microcirculation Research Group, Department of Oncology,
School of Medicine, University of Sheffield, Sheffield, United Kingdom, 4 Department of Medical
Pharmacology and Physiology, School of Medicine, University of Missouri, Columbia, Missouri, United States
of America, 5 Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri, United
States of America, 6 Department of Biotechnical & Clinical Laboratory Sciences, University at Buffalo,
Buffalo, New York, United States of America, 7 For-Robin, Inc, Buffalo, New York, United States of America
͞ Current address: Department of Biomedical Engineering, University of South Dakota, Sioux Falls, South
Dakota, United States of America‡ GAM and VVG are joint senior authors on this work.
* glinskiivl@health.missouri.edu (VVG); meiningerg@missouri.edu (GAM)
Abstract
Bone is a common site of metastasis for breast cancer and the mechanisms of metastasis
are not fully elucidated. The purpose of our study was to characterize temporal and molecu-
lar dynamics of adhesive interactions between human breast cancer cells (HBCC) and
human bone marrow endothelium (HBME) with piconewton resolution using atomic force
microscopy (AFM). In adhesion experiments, a single breast cancer cell, MDA-MB-231
(MB231) or MDA-MB-435 (MB435) was attached to the AFM cantilever and brought into
contact with a confluent HBME monolayer for different time periods (0.5 to 300 sec). The
forces required to rupture individual molecular interactions and completely separate inter-
acting cells were analyzed as measures of cell-cell adhesion. Adhesive interactions
between HBME and either MB231 or MB435 cells increased progressively as cell-cell con-
tact time was prolonged from 0.5 to 300 sec due to the time-dependent increase in the num-
ber and frequency of individual adhesive events, as well as to the involvement of stronger
ligand-receptor interactions over time. Studies of the individual molecule involvement
revealed that Thomsen-Friedenreich antigen (TF-Ag), galectin-3, integrin-ȕ1, and integrin-
Į3 are all contributing to HBCC/HBME adhesion to various degrees in a temporally defined
fashion. In conclusion, cell-cell contact time enhances adhesion of HBCC to HBME and the
adhesion is mediated, in part, by TF-Ag, galectin-3, integrin-Į3, and integrin-ȕ1.
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Introduction
Bone is one of the major sites of breast cancer metastasis. Seventy percent of patients suffering
from advanced breast cancer develop bone metastasis [1]. There are currently no effective
therapies available to prevent or treat breast cancer metastasis to the bone [2–3]. Metastasis is
a very complex process, which begins with successful escape of tumor cells from the primary
site, penetration into and survival within the circulation, arrest and extravasation at remote
sites, and culminates with invasion of target tissue and proliferation of metastatic lesions [4–
7]. Adherence of a circulating tumor cell to vascular endothelial cells is an essential process for
extravasation from the vasculature [7–10]. The mechanisms regulating metastatic tumor cell
interactions with endothelial cells in distant organs are incompletely understood, despite
numerous biological and clinical studies investigating the pathogenesis of cancer metastasis
[11–18]. A better understanding of the characteristics of interactions between tumor cells and
endothelial cells, and the molecular mechanisms underpinning these interactions, continues
to be a key for developing approaches to reduce the incidence of metastasis and for the devel-
opment of new therapeutic and diagnostic strategies.
Several molecules such as Thomsen-Friedenreich antigen (TF-Ag), galectin-3 (Gal-3) and
different integrins are involved in adhesive interactions between cancer cells and endothelial
cells [11,13,19]. TF-Ag is a disaccharide galactose Č1-3N-acetyl galactosamine conjugated to
proteins by an O-serine or O-threonine linkage and is expressed on the cell surface of most
human carcinomas, including breast cancer cells [20–22]. This well-defined carbohydrate anti-
gen plays a leading role in the initial adhesion of breast cancer cells to vascular endothelium by
specifically interacting with endothelial Gal-3 [11]. Gal-3 is a carbohydrate-binding protein
expressed in most human cells, including tumor and endothelial cells [23–25]. However, only
the Gal-3 expressed in endothelium, rather than in tumor cells, mediates tumor/endothelial
cell adhesion via interactions with cancer associated TF-Ag [13]. Gal-3 is commonly present in
endothelial cytoplasm and can translocate to the cell surface upon endothelial activation by
TF-Ag expressing cancer cells [11,13,21,26]. Integrins are transmembrane adhesion proteins
that form heterodimers of alpha and beta subtypes and are expressed in both tumor and endo-
thelial cells [19,27–28]. It has been shown that integrin ċ3Č1 (ċ3Č1) expressed in cancer cells
not only promotes cancer invasion [29–31], but also mediates cancer cell adhesion to vascular
endothelium in metastasis [32]. In addition, ċ3Č1 expressed in endothelial cells is proposed to
play an important role in stabilizing TF-Ag/Gal-3 mediated tumor-endothelial adhesion [13].
Atomic force microscopy (AFM) is a highly sensitive force measuring technique that has been
proven to be useful for investigating the adhesive interactions of living cells under physiological
conditions [33–34]. Quantitation of adhesion forces between cancer and endothelial cells is
obtained using AFM single-cell force spectroscopy in which a single cancer cell is attached to the
tip of a cantilever and brought into contact with an endothelial monolayer that grows on a sub-
strate. The ligand-receptor rupture events and total adhesion forces are calculated from the canti-
lever deflections monitored during cantilever retraction [34–35]. In the present study, we used
AFM to characterize adhesive interactions between individual human breast cancer cells and a
human bone marrow endothelial (HBME) cell monolayer and identify molecules that are
involved in the adhesion of breast cancer cells to HBME with functional antibodies.
Materials and methods
Cell lines, culture and preparations
The HBME line HBMEC-60 was kindly provided by Dr. C. E. van der Schoot, University of
Amsterdam (Amsterdam, The Netherlands). The HBMEC-60 cells were immortalized using
Single-cell force spectroscopy analysis of tumor cell adhesion to the endothelium
PLOS ONE | https://doi.org/10.1371/journal.pone.0204418 September 20, 2018 2 / 16
company, For-Robin Inc., but does not receive any
salary or remuneration from the For-Robin Inc.
company at this time or at any time in the past.
For-Robin Inc. had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The specific role of
this author is articulated in the ‘author
contributions’ section.
Competing interests: The authors have the
following interests: K.R.O. owns the company, For-
Robin Inc., which has licensed the JAA-F11
antibody from the University at Buffalo. The
University at Buffalo and K.R.O. have the patent for
the JAA-F11 antibody (Therapeutic use of anti-TF-
Antigen antibody US Patent NO 7,374,755). K.R.O.
does not receive any salary or remuneration from
the For-Robin Inc. company at this time or at any
time in the past. This does not alter the authors’
adherence to PLOS ONE policies on sharing data
and materials.
the amphotrophic helper-free retrovirus pLXSN16 E6/E7 and have shown to maintain their
normal phenotype and adhesive properties, specifically their ability to bind hematopoietic pro-
genitor cells [36]. Basal Medium 200 (Invitrogen) supplemented with 20% fetal bovine serum
(FBS, Atlanta Biologicals, Lawrenceville, GA, USA), gentamicin (Invitrogen) and low-serum
growth supplement (Invitrogen) containing hydrocortisone, human fibroblast growth factor,
heparin, and human epidermal growth factor was utilized for growing HBMEC-60. Highly met-
astatic human breast cancer cell lines, MDA-MB-231 (MB231) purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA), and MDA-MB-435 (MB435) kindly provided
by Dr. J. Price (M.D. Anderson Cancer Center, Houston, TX), were used in this study. Both
tumor cell lines were routinely cultured in RPMI 1640 medium (Invitrogen) supplemented
with 10% FBS, L-glutamine and gentamicin. All cells were maintained as monolayer cultures in
a humidified incubator (Heraeus Instruments, Newtown, CT) in 5% CO2 at 37˚C.
For adhesion experiments, endothelial cells were plated in collagen-I coated Petri dishes
(BD Bioscience) containing endothelial culture media. Cells were generally grown for 2 to 3
days to achieve confluence. In order to avoid possible variance introduced by cell passage and
culture period, cells were used at a similar range of passages and seeded at initial densities pro-
ducing the desired degree of confluence within 2–3 days. To avoid over-crowding, endothelial
cells were used for AFM experiments within 16 hours of reaching a confluent monolayer. Cells
were washed once and the growing media was replaced with serum-free, CO2 independent
medium (CO2IM, Invitrogen) before an experiment.
MB231 or MB435 cells at 40–50% confluence were detached in Cell Dissociation Buffer
(Invitrogen) before an experiment. After centrifugation, cells were re-suspended in CO2IM
and used for AFM cantilever attachment. All cancer and endothelial cells were allowed to
equilibrate for 15 min in CO2IM in the atmosphere at room temperature prior to AFM experi-
ments, and continuously maintained in the same conditions during the experiments.
Antibodies and other reagents
The following functional antibodies were used in this study: anti-TF-Ag antibody produced by
JAA-F11 hybridoma [37]; mouse monoclonal anti-human integrin ċ3 (ċ3, clone P1B5, Milli-
pore); anti-human integrin Č1 (Č1, HUTS-21, BD Pharmingen); anti-human integrin Č1 acti-
vating (activ Č1, P4G11, Millipore); and rat anti-human/mouse Gal-3 (M3/38, Santa Cruz
Biotech). Other reagents used in the study are: biotinamidocaproyl labeled BSA (Sigma-
Aldrich); Streptavidin (Sigma-Aldrich); Biotinylated concanavalin A (Con A, Sigma-Aldrich);
and 16% paraformaldehyde (Electron Microscopy Sciences).
Atomic force microscopy
All AFM experiments including measurements of cell-cell adhesion were performed using an
Asylum Research AFM System (Model MFP-3D-BIO, Asylum Research, Santa Barbara, CA)
with IGOR Pro software (WaveMetrics Inc., Oregon). The system was mounted on an inverted
optical microscope (Model IX81, Olympus America Inc.).
Cantilever functionalization and cell attachment
Tipless nitride cantilevers (MLCT-O10, Bruker Corp.) with a nominal spring constant of 30
pN/nm were used for measurements of cell adhesion force. Cantilevers were calibrated after a
given experiment using the thermal noise method [38]. The measured spring constants were
typically found to be between 8 and 14 pN/nm. The cantilever functionalization with Con A
was performed following procedures that were previously described by Zhang et al. [39].
Briefly, the cantilevers were treated in 0.5 mg/ml biotin labeled BSA overnight, then washed
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three times in PBS followed by incubation in 0.5 mg/ml streptavidin. The cantilevers were
finally incubated in 0.5 mg/ml biotinylated Con A at room temperature and rinsed in PBS.
The functionalized probe was mounted on the AFM head and placed in a culture dish that
was on the microscope stage and contained suspended cancer cells in CO2IM. Cancer cell to
cantilever attachment was performed manually under the optical microscope. Single cancer
cells of similar size were selected in order to keep the cell contact area as consistent as possible
throughout experiments. The tip of the Con A-coated cantilever was aligned with the center of
the cell and gently lowered onto the cell for 1 sec. The cancer cell was lifted by retraction of the
cantilever and allowed to rest for 5 min to allow the cell to adhere firmly to the cantilever.
Cell-cell adhesion measurement
For detecting adhesive forces between cancer cells and the HBMEmonolayer, the cantilever
with a coupled cancer cell was introduced into a Petri dish containing the HBMEC-60 at con-
fluence. The attached tumor cell was positioned to come into contact with an endothelial cell-
cell junction (Fig 1). The endothelial junction was chosen to measure because these regions are
the putative sites of cell extravasation, and maximal adhesion forces have been reported for
these sites [14]. The range of cantilever force distance approach-retraction was adjusted to at
least 40 μm to make it possible to completely separate the tumor cell from the endothelial cells
when the cantilever retracts. The closed loop feedback mode of the piezoelectric position was
applied in the AFM system to minimize the vertical drift of the cellular probe [33]. The closed
Fig 1. Diagrams and representative pictures of cancer-endothelial cell adhesion measurement. A single cancer cell
is attached on the end of the Con A-coated tipless cantilever (A) and then brought into contact with the endothelial
(HBMEC-60) cell-cell junctions (B). After a defined contact time, the cantilever is retracted (C) until the cancer cell is
entirely separated from endothelial cells (D). The phase contrast image (E) shows an MB435 cell (white arrow)
attached to the cantilever and in contact with a HBMEC-60 cell-cell junction. Force curves (F) are acquired during the
cantilever approach (red) and retraction (blue), and the retraction curve is used to calculate adhesion forces. Scale bar
in E = 10 µm.
https://doi.org/10.1371/journal.pone.0204418.g001
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loop feedback mode of the piezoelectric position was default enabled in the AFM system in
order to keep constant the position of the cell-cell contact. The sampling frequency was set at
0.02 Hz, resulting in a cantilever velocity of 1.60 μm/s. The average cell-cell contact force was
522 pN. The contact-time dependence of cell-cell adhesion forces were measured by running
cantilever approach-retraction cycles that brought the cancer cell into contact with endothelial
cells for different cell-cell contact periods (0.5–300 sec) prior to cantilever retraction. Fifteen
curves were collected for each contact time point on one sample. For negative adhesion con-
trol, the cancer cell was brought into contact with the bottom of a hydrogel coated dish (Corn-
ing Incorporated, NY).
For adhesion experiments in samples treated with functional antibodies, baseline adhesion
forces between cancer and HBME cells were first obtained for cell-cell contact times of 0.5, 30,
and 60 sec. An antibody was then added into the dish and both cancer and HBME cells were
incubated with the antibody for 40 min at room temperature. Force experiments were repeated
in the presence of the antibody. One cancer cell used for adhesion measurements was defined
as one sample number (n).
Adhesion forces were analyzed from retraction curves with MATLAB and calculated in pN.
The force that is required to break a single ligand-receptor bond was defined as an individual
adhesive interaction (recorded as a rupture force) and the total force that was necessary to
completely separate the cancer cell from HBMEC-60 monolayer was defined as the aggregate
total (overall) force to rupture all adhesions (total adhesion force, adhesion strength). The
term “rupture” is used to define an abrupt decrease of deflection in the force curve. The retrac-
tion curve can contain a number of rupture events before the deflection returns to the original
level (i.e. when cantilever is free of mechanical loads). To isolate and calculate individual rup-
ture events, a protocol with three steps of filtering was incorporated in the data analysis pro-
gramming. The first threshold (1 nm) was set to filter the rupture by the size of change in
deflection and the second threshold (0.28) was set to filter the rupture by the slope of change
in deflection. If the rupture event passed both filters, the force curve sections before and after
the deflection change were linearly fitted, and the difference of deflection between these two
sections was tested against the third threshold (1 nm). Only rupture events that pass all three
filtering steps were recorded and calculated. The method was validated by comparing with
human eye to assure more than 95% rate of capturing of ruptures that could be detected by
human eye. The mean total adhesion forces for single cancer cells were calculated and further
averaged together for each group. For data from the cancer-HBME adhesion study with anti-
body treatment, a percentage of adhesion changes was calculated when the adhesion force
value from an antibody treated cell was divided by its own baseline. The distributions of rup-
ture forces were plotted using Origin ver. 8.6 software.
Statistical analysis
All data are expressed as a mean ± standard error of the mean (SEM). Percentage data from
cancer-HBME adhesion studies with treatments of functional antibodies were compared using
a paired t-test. Multiple comparisons for studies of the dependence of adhesion on contact-
time between the cancer cells and the endothelial cells were analyzed with ANOVA. A value of
P< 0.05 was considered significant for all comparisons.
Results
Cancer-HBME adhesion with cell-cell contact duration
By coupling the cancer cell to the end of AFM cantilever and bringing it into contact with cell-
cell junctions of the HBME monolayer for various cell-cell contact periods (0.5, 1, 2, 5, 10, 30,
Single-cell force spectroscopy analysis of tumor cell adhesion to the endothelium
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60, 120 and 300 sec), adhesions between individual cancer cells and HBME cells were quanti-
fied to observe the correlation between the cancer-endothelial cell adhesion and length of cell
contact time. Plotted in Fig 2 are typical AFM cantilever retraction curves that were recorded
in adhesion studies of MB435/MB231 to HBMEC-60 cells with various cell-cell contact times.
The increases in peak force and total separation force (area between the approach and retrac-
tion curves, see Fig 1F) with times for both cancer cell lines are similar, clearly indicating that
the force required for separation of the tumor cell from the endothelial cells increased as a
Fig 2. Typical adhesion force curves of MB435 (A) and MB231 (B) to HBMEC-60 as a function of increasing
contact time. Representative curves for AFM cantilever retraction that were recorded in the experiments were plotted
for increasing lengths of cell-cell contact time in seconds (s). The total force required to separate the tumor cell from
the endothelial cells increased as a function of increasing contact time. The peak force in the aggregate curve for both
MB435 (A) and MB231 (B) cells shifts temporally to the right with increasing duration of contact. The vertical and
horizontal black bars stand for adhesion force (pN) and cantilever retraction distance (µm), respectively.
https://doi.org/10.1371/journal.pone.0204418.g002
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function of increasing contact time. It is seen that peak forces for both MB435 and MB231 in
the aggregate curve shift to the right with increasing duration of contact, indicating that a tran-
siently stretched deformation of cancer and/or endothelial cells occurred upon them separat-
ing at the initial retraction and suggesting adaptive cytoskeletal rearrangements to support
adhesion as well as engagement of more adhesion molecules. Correlations between cancer-
HBME adhesion strength and the duration of cell-cell contact are detailed in Fig 3. Although
the total adhesion forces in MB231 cells at all time points were lower than those in MB435,
adhesion forces increased progressively up to 23.79-fold (from 23.27 ± 5.73 to 553.64 ± 86.10
pN) for MB231 when cell-cell contact time was varied from 0.5 to 300 sec, while 9.29-fold
(68.81 ± 5.91 to 639.37 ± 62.50 pN) for MB435. Moreover, the two cancer cell lines displayed
similar time courses of adhesion to HBMEC-60, in which the adhesion strength in MB231
increased dramatically within the first 10 sec of contact and in MB435 within the first 30 sec,
and then more gradually. Force data at increasing cell-cell contact times for both MB231 and
MB435 cells were extremely significant (p< 0.001) by single factor ANOVA. As a negative
control, the cancer cells were brought into contact with a hydrogel-coated dish instead of an
endothelial monolayer (Fig 3). We found that total adhesion forces between cancer cells and
the hydrogel-coated dish were very low and did not increase when cell-dish contact time was
extended even for the longest contact period (300 sec). These results demonstrate that the
adhesion strength of MB231 and MB435 to HBMEC-60 cells is strongly dependent on cell-cell
contact time, especially within the initial 10 or 30 sec.
Fig 3. A relationship between the total cancer-HBME adhesion and duration of cell-cell contact. Adhesion
strength betweenMB231 andMB435 to HBMEC-60 cells was measured for different contact times: 0.5, 1, 2, 5, 10, 30,
60, 120, and 300 sec. The overall total adhesion forces in MB231 (asterisks) cells at all time points were lower than
those in MB435 (diamonds). In both cell lines, from 0.5 to 300 sec cell-cell contact time the total adhesion forces
increased progressively 23.79-fold (from 23.27 ± 5.73 to 553.64 ± 86.10 pN) and 9.29-fold (68.81 ± 5.91 to
639.37 ± 62.50 pN) for MB231 andMB435 respectively. Note similar time courses of adhesion dynamics to HBMEC-
60 displayed by both cancer cell lines, whereas the adhesion force increased dramatically within the first 10 sec
(MB231) or 30 sec (MB435) of contact with HBMEC, and then more gradually As a negative control, the MB435
(triangles) and MB231(circles) cells were brought into contact with a hydrogel-coated dish instead of an endothelial
monolayer. p< 0.001 by ANOVA analysis.
https://doi.org/10.1371/journal.pone.0204418.g003
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Rupture forces in the contact-time dependent adhesion
To assess how the strength of individual ligand-receptor binding involved in cancer-HBME
adhesion changed with extended cell contact time, we analyzed individual rupture forces and
compared the magnitude and frequency of occurrence of the forces (Fig 4). The frequency
counts of detectable rupture events increased 3.89-fold (from 903 to 3516 counts) in MB435
and 15.39-fold (from 156 to 2401 counts) in MB231 from 0.5 to 300 sec of cell-cell contacts.
Changes in the force distribution histograms were similar in shape for both MB435 (Fig 4A)
and MB231 (Fig 4B) cells showing marked peak distribution shifting to the right as contact
time increased, which is indicative of the involvement of stronger ligand-receptor-cytoskeletal
adhesive interactions. Although, the possibility that simultaneous rupture of several weaker
Fig 4. Distributions of rupture forces detected during cancer-HBME adhesion with cell-cell contact times of 0.5,
1, 2, 5, 10, 30, 60, 120 and 300 sec.Note 3.89-fold increase (from 903 to 3516 counts) in the frequency counts of the
detectable rupture events for MB435 and 15.39-fold increase (from 156 to 2401 counts) for MB231 from 0.5 to 300 sec
of cell-cell contact. Also note a significant shift of the rupture force frequency distribution histograms to the right for
both cancer cell lines. Similar changes in histograms of rupture force distribution for both MB435 (A) and MB231 (B)
cells indicate that both the increase in frequencies of individual adhesion events and involvement of stronger ligand-
receptor interactions contributed to the change in total adhesion force over time.
https://doi.org/10.1371/journal.pone.0204418.g004
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ligand-receptor bonds could be reflected as a single abrupt decrease of deflection on the force
curve (and detected as a single rupture of a stronger adhesive bond) can never be excluded, for
the purpose of this study, each such event was accounted as an individual rupture. Collectively,
these data indicate that changes in both the number of adhesions and in magnitude of individ-
ual adhesion rupture forces are responsible for the contact time dependence of total cancer-
HBME adhesion forces.
Molecule involvements in cancer-HBME interactions
In order to identify different types of molecules supporting cancer-HBME adhesive interactions
and to observe whether the molecular involvements are time-dependent, we performed pre-incu-
bations of both cancer and HBME cells with function-blocking antibodies (10 µg/ml) against
TF-Ag, integrin Č1, integrin ċ3, and galectin-3 (Gal-3) for 45 min. Next, adhesion forces were
measured for cell-cell contact times of 0.5, 30 and 60 sec before (baseline) and after treatment
with the antibodies. CO2IM without antibody was used as a negative control, while an activating
anti-integrin Č1 (activ-Č1) antibody was used as a positive control. Changes in adhesion forces
were calculated and illustrated in Fig 5. Upon interaction betweenMB435 and HBMEC-60, adhe-
sions were significantly reduced to the various degrees by function-blocking antibodies (Fig 5A).
From contacts of 0.5 to 60 sec, the highest inhibition at 0.5 sec was seen with antibodies to TF-Ag
(-20.45 ± 7.92%, n = 10, p< 0.05) and Č1 (-24.89 ± 6.56%, n = 14, p< 0.05), which had descending
inhibitions with increase of contact, compared to the baseline; while ċ3 (-33.41 ± 4.18%, n = 11,
p< 0.01) and Gal-3 (-40.27 ± 3.68%, n = 10, p< 0.01) with the highest inhibitions at 60 sec, show-
ing ascending inhibitions with prolonged contact, when compared to the baseline. In the positive
control, activ-Č1 antibody induced the greatest adhesion (64.55 ± 12.05%, n = 10, p< 0.05) at 0.5
sec in the three time points, which is in agreement with what was seen in the group treated with
inhibiting Č1 antibody. There are significant time-dependencies at the contact time of 60 sec in ċ3
and Gal-3 antibody treated groups, compared to the 0.5 sec (p< 0.05).
In adhesion between MB231 and HBMEC-60 (Fig 5B), antibodies against TF-Ag (-23.26 ±
7.44%, n = 10, p< 0.05) and Č1 (-23.81 ± 5.07%, n = 8, p< 0.05) revealed inhibitions in the
adhesion for 60 sec of the contact, but not for 0.5 and 30 sec. Antibody to Gal-3 inhibited sig-
nificantly adhesion for 30 sec (-33.40 ± 5.89%, n = 7, p< 0.05) and 60 sec (-41.71 ± 10.51% for
60 sec, n = 7, p< 0.05) contact time, when compared to the baseline; and Gal-3 antibody had
significantly time-dependent inhibitions for 30- and 60-sec contact time (p< 0.05), compared
to the 0.5 sec (-2.95 ± 9.94%, n = 7). Inhibition of MB231 adhesion by TF-Ag and Č1 antibodies
for 0.5 sec contact time, as well as by ċ3 antibody for all three time points did not reach statisti-
cal significance due to the insufficient sample size.
Analyses of rupture forces collected from cancer-HBME adhesion measurements demon-
strated that treatments with inhibitory antibodies reduced the number of observed rupture
forces and changed the shape of the frequency distribution as well. Plotted in Fig 6 are distri-
bution histograms created fromMB435-HBMEC-60 adhesion for cell-cell contacts of 0.5 sec
(Fig 6A, 6D, 6G, 6J, 6M, 6P and 6S), 30 sec (Fig 6B, 6E, 6H, 6K, 6N, 6Q and 6T), and 60 sec
(Fig 6C, 6F, 6I, 6L, 6O, 6R and 6U) before and after antibody (10 µg/ml) treatment. There
were no obvious changes seen in rupture distribution in CO2IM treated control (Fig 6A–6C).
Function-inhibiting antibody to TF-Ag (Fig 6D–6F), noticeably reduced the number of the
weakest (30–50 pN) and midrange (50–80 pN) adhesions at the earliest 0.5 sec time point (Fig
6D), which apparently prevented the formation of stronger adhesions at 30 and 60 sec time
points (Fig 6E and 6F). Anti-Gal-3 antibody had some inhibitory effect on midrange (50–80
pN) adhesions at 0.5 sec time point (Fig 6G), but a very pronounced inhibition of adhesions
across the entire spectrum at 30 and 60 sec (Fig 6H and 6I), indicating that Gal-3 involvement
Single-cell force spectroscopy analysis of tumor cell adhesion to the endothelium
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may require additional time to unfold, and that stronger, integrin-mediated adhesive events,
may depend on preceding Gal-3 mobilization. Function-blocking antibodies against integrins
ċ3 (Fig 6J–6L) and Č1 (Fig 6M–6O) had limited inhibitory effect at 0.5 sec (although more pro-
nounced for Č1 suggesting that other Č1 integrins in addition to ċ3Č1 could be involved). At
30 and 60 sec time points, however, both anti-ċ3 and anti-Č1 caused more significant inhibi-
tion of adhesions across the entire spectrum including the stronger (>80 pN) adhesions. As
expected, a mixture of all four function blocking antibodies (Fig 6P–6R) caused substantially
more significant inhibition of adhesions across the entire spectrum than any of the antibodies
did alone.
Fig 5. Changes in cancer-HBME total adhesion force with antibody treatment. In adhesion betweenMB435 and
HBMEC-60 (A), from 0.5 to 30 to 60 sec contact times, total adhesion forces were significantly reduced by antibodies
to TF-Ag and Č1 showing descending inhibition dynamics with the highest inhibition at 0.5 sec, compared to the
baseline; while anti-ċ3 and anti-Gal-3 showed ascending inhibition dynamics with the highest inhibition at 60 sec. As
positive control, activating Č1 antibody (Activ Č1) induced the greatest adhesion (64.55%) at 0.5 sec, which is in
agreement with what was observed with inhibiting anti-Č1 antibody. In adhesion betweenMB231 and HBMEC-60 (B),
significant inhibition was observed at the 60 sec contact time with antibodies against TF-Ag (-23.26%), Č1 (-23.81%)
and Gal-3 (-41.71%), but not statistically significant with anti-ċ3, compared to the baseline. p< 0.05; p< 0.01, vs the
baseline. § p< 0.05 vs 0.5 sec contact. n> 6.
https://doi.org/10.1371/journal.pone.0204418.g005
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Similarly, in MB231-HBMEC-60 adhesion experiments, there were no obvious changes in
rupture distribution in CO2IM treated control experiments (Fig 7A–7C). Anti-TF-Ag
JAA-F11 antibody (Fig 7D–7F), caused noticeable reduction in the number of the weakest
(30–50 pN) and midrange (50–80 pN) adhesions at the earliest (0.5 sec) time point (Fig 7D),
which prevented the formation of stronger adhesions at 30 and 60 sec time points (Fig 7E and
7F). As with MB435, anti-Gal-3 antibody caused some inhibitory effect on midrange (50–80
pN) adhesions at 0.5 sec time point (Fig 7G), and very pronounced inhibition of adhesions
Fig 6. Distribution frequencies of rupture forces collected fromMB435-HBMEC-60 adhesion for cell-cell contacts
of 0.5 (A,D,G,J,M,P, and S), 30 (B,E,H,K,N,Q, and T) and 60 (C,F,I,L,O,R, and U) seconds before and after
antibody (10 µg/ml) treatments. There were no changes seen in rupture distribution in CO2IM treated control (A, B
and C). Function-inhibiting antibodies to TF-Ag (D, E and F), Gal-3 (G, H and I), ċ3 (J, K and L) and Č1 (M, N and O)
decreased the number of rupture events compared to the respective baselines. Note reduced number of the weakest
(30–50 pN) and midrange (50–80 pN) adhesions at the earliest 0.5 sec time point caused by anti-TF-Ag (D), which
apparently prevented the formation of stronger adhesions at 30 and 60 sec time points (E and F). Anti-Gal-3 antibody
caused rather limited inhibitory effect on the weakest (30–50 pN) and midrange (50–80 pN) adhesions at 0.5 sec time
point (G) It demonstrated, however, a pronounced inhibition of adhesions across the entire spectrum at 30 and 60 sec
(H and I), indicating that Gal-3 involvement requires additional time to unfold, and that stronger, integrin-mediated
adhesive events, may depend on preceding Gal-3 mobilization. Limited inhibitory effect was detected with function-
blocking antibodies against integrins ċ3 and Č1 at 0.5 sec (J and M respectively). At 30 and 60 sec time points, however,
both anti-ċ3 (K and L) and anti-Č1 (N and O) caused more significant inhibition of adhesions across the entire
spectrum including the stronger (>80 pN) adhesions. A combination of the four function-blocking antibodies (P-R)
showed a greater inhibitory effect than any of the antibodies alone (D to O). In the positive control (S-U), the function-
activating antibody to Č1 increased the number of detectable ruptures.
https://doi.org/10.1371/journal.pone.0204418.g006
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across the entire spectrum at 30 and 60 sec (Fig 7H and 7I). The dynamics of inhibition of
MB231 cells by function-blocking antibodies against integrins ċ3 (Fig 7J–7L) and Č1 (Fig 7M–
7O) were also similar to those of MB435. That is, they both had rather limited inhibitory effect
at 0.5 sec (Fig 7J and 7M), but caused more significant inhibition of adhesions across the entire
spectrum at 30 and 60 sec time points (Fig 7K, 7L, 7N and 7O). Again, as with MB435, the mix-
ture of all four antibodies caused significantly more pronounced inhibition across the entire
spectrum of adhesions at all 3 time points (Fig 7P–7R).
Collectively, these results are in agreement with our previously proposed model whereby
tumor/endothelial cell adhesion is initiated by TF-Ag interactions with endothelial Gal-3
Fig 7. Distribution frequencies of rupture forces collected fromMB231-HBMEC-60 adhesion experiments for
cell-cell contact times of 0.5 (A,D,G,J,M,P, and S), 30 (B,E,H,K,N,Q, and T) and 60 (C,F,I,L,O,R, and U) sec before
and after antibody (10 µg/ml) treatment.No obvious changes were detected in rupture distribution in CO2IM
treated controls (A-C) compared to the baseline. Noticeable reduction in the number of the weakest (30–50 pN) and
midrange (50–80 pN) adhesions at the earliest (0.5 sec) time point was caused by anti-TF-Ag JAA-F11 antibody (D),
which also prevented the formation of stronger adhesions at 30 and 60 sec time points (E and F). Only minimal
inhibitory effect on midrange (50–80 pN) adhesions was detected at the earliest (0.5 sec) time point with anti-Gal-3
antibody (G). However, this same antibody caused very pronounced inhibition across the entire spectrum of adhesions
at 30 and 60 sec (H and I). The inhibitory effect of function blocking anti-ċ3 and anti-Č1 antibodies was rather limited
at 0.5 sec time point (J and M respectively). They did cause, however, noticeable inhibition of adhesions across the
entire spectrum at 30 and 60 sec time points (K, L, N and O). The inhibitory effect of the mixture of all four antibodies
was significantly more pronounced across the entire spectrum of adhesions at all three time points (P-R) than any of
the function blocking antibodies alone. In the positive control (S-U), the function-activating antibody to Č1 increased
the number of detectable ruptures.
https://doi.org/10.1371/journal.pone.0204418.g007
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causing translocation and clustering of the later at the endothelial cell membrane and followed
by the mobilization of ċ3Č1 integrin further strengthening and stabilizing these adhesive inter-
actions [13].
Discussion
Metastatic cell interactions with vascular endothelium in distant organs constitute an essential
component of hematogenous cancer metastasis. Tumor/endothelial cell adhesion is not simply
an act of the mechanical attachment of circulating blood-borne metastatic cells to the vessel
wall, but an extremely complex and dynamic process. This process is tightly regulated on
many levels [13] and involves highly orchestrated interactions of multiple ligand-receptor
pairs, cytoskeleton rearrangements, and major signaling pathways. In this study, we have used
AFM to investigate temporal dynamics of the adhesion of two human metastatic breast carci-
noma cell lines, MDA-MB-231 and MDA-MB-435, to human bone marrow endothelial cells
HBMEC-60. Not only did use of AFM provided for a quantitative characterization of cell-to-
cell adhesive interactions with unprecedented (piconewton) resolution, but also it afforded the
possibility for studying the process of maturation of tumor/endothelial cell adhesion via the
engagement of new, quantitatively and qualitatively distinct molecular events, as well as inter-
rogating the involvement of individual ligand-receptor pairs in the process.
Our results indicate that the strength of adhesion between endothelial cells and both
MB435 and MB231 cells increases dramatically within first 10–30 sec and then more gradually,
resulting in the total increase in adhesion strength for MB435 and MB231 cells 23.79-fold and
9.29-fold respectively within 300 sec (Fig 3). Evidently, this change occurs due to both the
increase in the number of individual adhesion events (3.89-fold for MB435 and 15.39-fold for
MB231), and involvement of qualitatively different (stronger) adhesions (Fig 4). These results
indicate that after the initial attachment of tumor cell to the endothelial cell via weaker adhe-
sive interactions, a rapid process of tumor-endothelial cell adhesion maturation and stabiliza-
tion takes place involving exponential increase in the number of adhesion molecules engaged
and development of much stronger individual adhesive interactions. This process can involve
translocation toward and clustering at the sites of adhesion the types of molecules already
engaged into tumor-endothelial cell interactions from the very beginning (for example, TF-Ag
on tumor cells and endothelial Gal-3) resulting in the multiplication of the adhesions and
strengthening of the overall bond between tumor and endothelial cells. It is likely as well to
involve the recruitment of new ligand-receptor pairs including molecules with stronger adhe-
sive properties such as integrins.
Recently, based mostly on prostate cancer experiments, we have proposed the model,
whereby adhesive interactions between tumor and endothelial cells initiated by cancer-associ-
ated TF-Ag causes translocation and clustering of the endothelium-expressed Gal-3 at the sites
of adhesion, which in turn signals mobilization of the ċ3Č1 integrin that strengthens and stabi-
lizes tumor/endothelial cell adhesion [13]. In this study, we have analyzed distribution fre-
quencies of rupture forces collected from AFM experiments utilizing function blocking
antibodies against TF-Ag, Gal-3, ċ3 and Č1 integrin. Although the AFM experiments were per-
formed on a different (much shorter) time scale, they have confirmed that these same mole-
cules play important role in breast carcinoma cell adhesion to bone marrow endothelium as
well. However, as none of these antibodies alone (or even all of them combined) were able to
inhibit tumor/endothelial cell adhesion completely, it is likely that additional adhesion mole-
cules are involved in the process. Further, based on the dynamics of the inhibition of tumor/
endothelial cell adhesion by anti-ċ3 and anti-Č1 antibodies in MB435 cell experiments it is
apparent that in addition to ċ3Č1 integrin, other Č1 integrin molecules could be involved.
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In summary, we have used AFM, a highly sensitive, robust method to characterize the tem-
poral course of adhesion between human breast cancer cells and an endothelial monolayer and
probe a number of molecules that are involved in the adhesive interaction between breast can-
cer cells and the endothelium. The AFM single-cell force spectroscopy provides unprecedented
precision, resolution and sensitivity for interrogating the involvement of various adhesion
molecules into the process of cancer metastasis.
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